Drug Profile


Alternative Names: PLX-3397

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator Plexxikon
  • Developer AstraZeneca; Barbara Ann Karmanos Cancer Institute; Centre Leon Berard; Columbia University; Merck & Co; National Cancer Institute (USA); Plexxikon; University of California at San Francisco
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Immunomodulators; Macrophage colony stimulating factor receptor antagonists; Proto oncogene protein c-akt inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pigmented villonodular synovitis
  • Phase II Glioblastoma; Malignant melanoma; Prostate cancer
  • Phase I/II Breast cancer; Leukaemia; Peripheral nervous system diseases; Sarcoma; Solid tumours
  • Phase I Colorectal cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • No development reported Neurological disorders; Rheumatoid arthritis
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 03 Apr 2017 University Hospital Southampton NHS Foundation Trust plans the POLERISE phase I/II trial for Prostate cancer (Late-stage disease, First-line therapy, Combination therapy, Hormonal refractory, Metastatic disease) in United Kingdom
  • 01 Jan 2017 Phase-I/II clinical trials in Malignant melanoma (First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in China (PO) (NCT02975700)
  • 30 Nov 2016 Plexxikon plans a phase I/II trial for Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease) in South Korea and China (PO) (NCT02975700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top